Given the unique dependence of MLL-FPs on aberrant SAM–dependent activating H3K79 methylation by DOT1L to maintain leukemic potential, we investigated perturbation of Met/SAM metabolism as a novel therapeutic strategy to disrupt abnormal activating epigenetic methylation driving MLL-R leukemias. Here, KMT2A is linked to leukemia.